Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/12679
Full metadata record
DC FieldValueLanguage
dc.contributor.authorXenos, M.en
dc.contributor.authorGirdhar, G.en
dc.contributor.authorAlemu, Y.en
dc.contributor.authorJesty, J.en
dc.contributor.authorSlepian, M.en
dc.contributor.authorEinav, S.en
dc.contributor.authorBluestein, D.en
dc.date.accessioned2015-11-24T17:22:54Z-
dc.date.available2015-11-24T17:22:54Z-
dc.identifier.issn0021-9290-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/12679-
dc.rightsDefault Licence-
dc.subjectprosthetic heart valves (phv)en
dc.subjectmechanical heart valves (mhv)en
dc.subjectmechanical circulation support (mcs)en
dc.subjectcomputational fluid dynamicsen
dc.subjectplatelet activationen
dc.subjectplatelet assaysen
dc.subjectthrombogenic performanceen
dc.subjectmechanical heart-valvesen
dc.subjectinduced platelet activationen
dc.subjectfluid-structure interactionen
dc.subjectfree emboli formationen
dc.subjectblood damageen
dc.subjectflow-throughen
dc.subjectnumerical-simulationen
dc.subjectshear-stressen
dc.subjectexperimental validationen
dc.subjectmathematical-modelen
dc.titleDevice Thrombogenicity Emulator (DTE) - Design optimization methodology for cardiovascular devices: A study in two bileaflet MHV designsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDOI 10.1016/j.jbiomech.2010.04.020-
heal.identifier.secondary<Go to ISI>://000282112300023-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0021929010002320/1-s2.0-S0021929010002320-main.pdf?_tid=cc8d9e80f66d9aeea386a9f381956158&acdnat=1339396086_2cb174bf4da17da23c79c70f92baf593-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Μαθηματικώνel
heal.publicationDate2010-
heal.abstractPatients who receive prosthetic heart valve (PHV) implants require mandatory anticoagulation medication after implantation due to the thrombogenic potential of the valve. Optimization of PHV designs may facilitate reduction of flow-induced thrombogenicity and reduce or eliminate the need for post-implant anticoagulants. We present a methodology entitled Device Thrombogenicty Emulator (DTE) for optimizing the thrombo-resistance performance of PHV by combining numerical and experimental approaches. Two bileaflet mechanical heart valves (MHV) designs, St. Jude Medical (SJM) and ATS, were investigated by studying the effect of distinct flow phases on platelet activation. Transient turbulent and direct numerical simulations (DNS) were conducted, and stress loading histories experienced by the platelets were calculated along flow trajectories. The numerical simulations indicated distinct design dependent differences between the two valves. The stress loading waveforms extracted from the numerical simulations were programmed into a hemodynamic shearing device (HSD), emulating the flow conditions past the valves in distinct 'hot-spot' flow regions that are implicated in MHV thrombogenicity. The resultant platelet activity was measured with a modified prothrombinase assay, and was found to be significantly higher in the SJM valve, mostly during the regurgitation phase. The experimental results were in excellent agreement with the calculated platelet activation potential. This establishes the utility of the DTE methodology for serving as a test bed for evaluating design modifications for achieving better thrombogenic performance for such devices. (C) 2010 Elsevier Ltd. All rights reserved.en
heal.publisherElsevieren
heal.journalNameJ Biomechen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΜΑΘ

Files in This Item:
File Description SizeFormat 
Xenos-2010-Device Thrombogenici.pdf2.31 MBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons